ASX:IXC Invex Therapeutics (IXC) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free IXC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield219.18%Price TargetN/A Stock AnalysisStock Analysis Get Invex Therapeutics alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Invex TherapeuticsInvex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him IXC Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive IXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:IXC CUSIPN/A CIKN/A Webwww.invextherapeutics.com Phone61 8 6382 0137FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-40.06% Return on Assets-26.57% Debt Debt-to-Equity RatioN/A Current Ratio6.38 Quick Ratio29.36 Sales & Book Value Annual Sales$1.26 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares75,150,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.43 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Narelle Warren B.Com.L.L.B., B.Com, LLB, CFO & Company SecretaryDr. Thomas Duthy M.B.A.Ph.D., Executive DirectorKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersMegan BaldwinSold 400,000 sharesTotal: $33,600.00 ($0.08/share)Thomas (Tom) DuthySold 285,661 sharesTotal: $21,424.58 ($0.08/share)Thomas (Tom) DuthyBought 178,738 shares on 8/24/2023Total: $32,172.84 ($0.18/share) IXC Stock Analysis - Frequently Asked Questions Is Invex Therapeutics a good dividend stock? Invex Therapeutics (ASX:IXC) pays an annual dividend of A$0.19 per share and currently has a dividend yield of 219.18%. IXC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. This page (ASX:IXC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
